Journal
CELL
Volume 185, Issue 14, Pages 2422-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2022.06.005
Keywords
-
Categories
Funding
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China [2018-I2M-2-002]
- Schmidt Futures
- Red Avenue Foundation
- Oak Foundation
- Wellcome [101122/Z/13/Z, 090532/Z/09/Z, 203141/Z/16/Z]
- UKRI MRC [MR/N00065X/1]
- Medical Research Council [MC_PC_19059]
- NIHR Oxford BRC
- UK Research and Innovation
- Coalition for Epidemic Preparedness Innovations
- National Institute for Health Research (NIHR)
- NIHR Oxford Biomedical Research Centre
- Thames Valley and South Midland's NIHR Clinical Research Network
- UK Department of Health and Social Care
- UK Coronavirus Immunology Consortium (UK-CIC)
- Huo Family Foundation
- NIH [WT109965MA, U19 I082360]
- NIHR Global Research Professorship [NIHR300791]
- Wellcome Trust [101122/Z/13/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
The Omicron variant of SARS-CoV-2 has rapidly spread globally and has evolved into different sublineages, with BA.4 and BA.5 dominating in South Africa. These sublineages show reduced neutralization by vaccine and naturally immune serum, indicating the possibility of repeat Omicron infections.
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa???s Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the recep-tor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, sig-nificant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available